Navigation Links
Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles 'Snuffy' Myers Announces Vitamin D Clinical Trials
Date:4/16/2008

CHARLOTTESVILLE, Va., April 16 /PRNewswire-USNewswire/ -- The Foundation for Cancer Research and Education (FCRE) announced today that prostate cancer oncologist and survivor, Dr. Charles "Snuffy" Myers, will lecture on new treatments for prostate cancer at Westminster at Lake Ridge, VA on April 26, 2008 from 9:30 AM--12:30 PM.

"With the recent press around prostate cancer vaccines, people are very excited about new treatments," Myers says. "The good news is there are many things people can do to prevent recurrence before it starts."

Some of those treatments include:

-- Celebrex

-- Proscar/Avodart

-- Leukine

-- Calcitriol

-- Avastin

-- Mediterranean heart healthy diet

-- Vitamin D3

-- Pomegranate.

In addition, to his lecture, Dr Myers will also be announcing his new clinical trials meant to investigate one of the most promising of those treatments -- vitamin D3.

"The current research and what I see in my patients suggests that vitamin D can dramatically slow the PSA doubling times that indicate recurrent and often lethal disease," Myers says. "The trials are meant to show Vitamin D3's role in slowing or stopping the growth of prostate cancer that has recurred after surgery or radiation in a much more substantive way." Information about the trial and how to participate will be provided at the meeting.

The program, located at Westminster at Lake Ridge, 12191 Clipper Drive, Lake Ridge or Woodbridge, VA, is free of charge and includes a heart-healthy buffet breakfast for all attendees. Sponsors include FCRE, The Virginia Prostate Cancer Coalition, Us TOO, Westminster at Lake Ridge, and Potomac Hospital.

This will be the fourth time Myers has presented at Lake Ridge but the first time he publicly announces the foundation's new research efforts.

"Myers's always provides informative lectures," notes Richard Gillespie, head of the Lake Ridge Us TOO Chapter. "But we're eager to hear about the new trials Dr. Myers is working on."

For information on the event or directions please call Richard Gillespie at 703-497-0628.

About FCRE

The Foundation for Cancer Research and Education (FCRE) is dedicated to cutting edge research and clinically driven educational programs. A streamlined organization with specific research goals, FCRE's mission is to prolong patients' lives with focused research strategies. For more information or for a list of FCRE's outreach programs call 800-305-2432 or go to http://www.cancer-foundation.org.


'/>"/>
SOURCE Foundation for Cancer Research and Education
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
3. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Prostate Cancer Treatment Centre Receives Funding for Clinical Trials
11. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and ... Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD ... that can be easily incorporated into liquid products, while reducing costs to end users. ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
Breaking Medicine News(10 mins):